RT Journal Article
T1 Mechanisms of cardiovascular disorders in patients with chronic kidney disease: a process related to accelerated senescence
A1 Carracedo Añón, Julia María
A1 Alique, Matilde
A1 Vida, Carmen
A1 Bodega, Guillermo
A1 Ceprián, Noemí
A1 Morales Ruiz, Enrique
A1 Praga, Manuel
A1 De Sequera Ortiz, Patricia
A1 Ramírez, Rafael
AB Cardiovascular diseases (CVDs), especially those involving a systemic inflammatory process such as atherosclerosis, remain the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). CKD is a systemic condition affecting approximately 10% of the general population. The prevalence of CKD has increased over the past decades because of the aging of the population worldwide. Indeed, CVDs in patients with CKD constitute a premature form of CVD observed in the general population. Multiple studies indicate that patients with renal disease undergo accelerated aging, which precipitates the appearance of pathologies, including CVDs, usually associated with advanced age. In this review, we discuss several aspects that characterize CKD-associated CVDs, such as etiopathogenic elements that CKD patients share with the general population, changes in the cellular balance of reactive oxygen species (ROS), and the associated process of cellular senescence. Uremiaassociated aging is linked with numerous changes at the cellular and molecular level. These changes are similar to those observed in the normal process of physiologic aging. We also discuss new perspectives in the study of CKD-associated CVDs and epigenetic alterations in intercellular signaling, mediated by microRNAs and/or extracellular vesicles (EVs), which promote vascular damage and subsequent development of CVD. Understanding the processes and factors involved in accelerated senescence and other abnormal intercellular signaling will identify new therapeutic targets and lead to improved methods of diagnosis and monitoring for patients with CKD-associated CVDs.
PB Frontiers Media
SN ESSN: 2296-634X
YR 2020
FD 2020-03-20
LK https://hdl.handle.net/20.500.14352/6301
UL https://hdl.handle.net/20.500.14352/6301
LA eng
NO Instituto de Salud Carlos III /Fondo Europeo de Desarrollo Regional(FEDER)
NO Universidad Complutense de Madrid/Banco de Santander
NO Universidad de Alcalá de Henares/Sociedad Española de Nefrología
NO Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12
DS Docta Complutense
RD 8 abr 2025